Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With CancerKevin C. Conlon, Thomas A. Waldmann, Carolyn K. Goldman et al.|Journal of Clinical Oncology|2014Cited by 714
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaquesThomas A. Waldmann, Stephen P. Creekmore, Enrico Lugli et al.|Blood|2011Cited by 194
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset ExpansionKevin C. Conlon, Thomas A. Waldmann, E. Lake Potter et al.|Clinical Cancer Research|2019Cited by 134
Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primatesEnrico Lugli, Mario Roederer, Carolyn K. Goldman et al.|Blood|2010Cited by 123
CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter TrialNirali N. Shah, Richard Aplenc, Sarah K. Tasian et al.|Blood|2023Cited by 62